JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Omnicell Inc

Fechado

SetorSaúde

30.47 0.3

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.88

Máximo

30.56

Indicadores-chave

By Trading Economics

Rendimento

-23M

-7M

Vendas

-37M

270M

P/E

Médio do Setor

63.044

40.048

EPS

-0.151

Margem de lucro

-2.604

Funcionários

3,620

EBITDA

-46M

-12M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+43.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-488M

1.4B

Abertura anterior

30.17

Fecho anterior

30.47

Sentimento de Notícias

By Acuity

23%

77%

53 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Omnicell Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 21:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 de ago. de 2025, 21:21 UTC

Ganhos
Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 de ago. de 2025, 21:30 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 21:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 de ago. de 2025, 21:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 20:25 UTC

Conversa de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss $938M >RIG

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss/Shr $1.06 >RIG

4 de ago. de 2025, 20:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 de ago. de 2025, 20:15 UTC

Ganhos

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 de ago. de 2025, 20:13 UTC

Ganhos

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 de ago. de 2025, 20:09 UTC

Ganhos

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 de ago. de 2025, 20:06 UTC

Ganhos

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 de ago. de 2025, 19:41 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 de ago. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 de ago. de 2025, 19:07 UTC

Conversa de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 de ago. de 2025, 18:27 UTC

Conversa de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparação entre Pares

Variação de preço

Omnicell Inc Previsão

Preço-alvo

By TipRanks

43.38% parte superior

Previsão para 12 meses

Média 42.67 USD  43.38%

Máximo 57 USD

Mínimo 32 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Omnicell Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

4

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

24.23 / 30.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

53 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.